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Abstract
Background. Renal dysfunction is associated with increased morbidity and mortality in intensive care patients. In most cases the
glomerular ﬁltration rate (GFR) is estimated based on serum creatinine and the Modiﬁcation of Diet in Renal Disease
(MDRD) formula, but cystatin C-estimated GFR is being used increasingly. The aim of this study was to compare creatinine
and MDRD and cystatin C-estimated GFR in intensive care patients.
Methods. Retrospective observational study was performed, on patients treated within the general intensive care unit (ICU)
during 2004–2006, in a Swedish university hospital.
Results. GFR markers are frequently ordered in the ICU; 92% of the patient test results had cystatin C-estimated GFR
(eGFRcystatinC) £ 80 mL/min/1.73 m
2, 75% had eGFR £ 50 mL/min/1.73 m
2, and 30% had eGFR £ 20 mL/min/1.73 m
2.I n
contrast, only 46% of the patients had reduced renal function assessed by plasma creatinine alone, and only 47% had
eGFRMDRD £ 80 mL/min/1.73 m
2. The mean difference between eGFRMDRD and eGFRcystatinC was 39 mL/min/1.73 m
2 for
eGFRcystatinC values £ 60 mL/min/1.73 m
2.
Conclusions. GFR is commonly assessed in the ICU. Cystatin C-estimated GFR yields markedly lower GFR results than plasma
creatinine and eGFRMDRD. Many pharmaceuticals are eliminated by the kidney, and their dosage is adjusted for kidney
function. Thus, the differences in GFR estimates by the methods used indicate that the GFR method used in the intensive care
unit may inﬂuence the treatment.
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Introduction
Glomerular ﬁltration rate (GFR) is generally accepted
as the best overall indicator of renal function and is
therefore an important marker for renal disease.
Reduced GFR is one of the most important compli-
cations in critically ill patients and is associated with
increased morbidity and mortality in the intensive
care unit (ICU) population (1–4). Furthermore,
reduced GFR inﬂuences the clearance of many phar-
maceuticals used today. Thus, in many cases the
recommended dose of a drug has to be adjusted
depending on the patient’s GFR. For instance, the
dosage of antibiotics and cytotoxic drugs is usually
prescribed according to GFR. Monitoring renal func-
tion is thus very important in the management of
intensive care patients, and GFR markers are fre-
quently used for this purpose, necessitating conve-
nient and reliable GFR markers. Inulin, iohexol, and
51Cr-EDTA clearances are considered as ‘gold stan-
dards’ for GFR measurements in Sweden (5–7). The
disadvantage with these assays, and creatinine clear-
ance with urine collection, is that they are cumber-
some, costly, and associated with long turn-around
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DOI: 10.3109/03009734.2010.526724times, which may delay initiation and adjustment of
treatment. They are thus less suitable for an intensive
care unit requiring rapid decisions and actions. Thus,
endogenous markers are usually preferred in the
intensive care setting. The ideal endogenous marker
should have a stable production rate, be unaffected by
pathological changes, lack protein binding, be freely
ﬁltered through the glomeruli, and lack reabsorption
or secretion. To date, no such marker has been
identiﬁed.
Serum or plasma creatinine is the most commonly
used GFR marker (8,9). Creatinine is an inexpensive
test widely available in clinical chemistry laboratories,
but the assay outcome is hampered by the inﬂuence of
several extrarenal factors such as age, gender, muscle
mass, physical activity, and diet (10,11). It is also
insensitive for small decreases in GFR, in the so-
called creatinine-blind GFR area, due to the non-
linear relationship between plasma concentration and
GFR (12).
Cystatin C is an endogenous polypeptide that is
more sensitive than serum creatinine for the detection
of small decreases in GFR and is reported not to be
inﬂuenced by inﬂammation, liver function, age, gen-
der, muscle mass, physical activity, or diet (13).
Human cystatin C has a plasma clearance of cystattin
C of 94% of the generally used GFR-marker,
51Cr-EDTA in the rat (14).
Previously, cystatin C assays were hampered by the
limited availability of the test, but cystatin C methods
have now been developed for clinical chemistry lab-
oratories making the test widely accessible. Cystatin C
can thus be analyzed with short turn-round times
providing rapid test results for intensive care, at costs
comparable to plasma creatinine analysis.
A recent meta-analysis has shown that cystatin C is
superior to plasma creatinine as a marker of renal
function (15). Another study has suggested that cysta-
tin C is superior to creatinine as a GFR marker in
critically ill patients (16).
The aim of this study was to assess the prevalence of
reduced GFR in this patient group using creatinine
and Modiﬁcation of Diet in Renal Disease (MDRD)
and cystatin C-estimated GFR, as several pharma-
ceuticals are prescribed according to renal function,
and to investigate the request frequency of laboratory
markers in an ICU, with special reference to GFR
markers.
Materials and methods
Study population
This study included all patients treated within the
general intensive care unit, Uppsala University
Hospital, during the time period 1 January 2004 to
1 September 2006. The total number of tests per year,
presented in Table I, was based on all requests during
the same time period. The Table thus also includes
requests for patients below 16 years of age and
requests without a valid test result (e.g. samples
that could not be analyzed due to insufﬁcient sample
volumes). For comparison between cystatin C
and creatinine results, only valid test results from
patients older than 16 years of age were included.
Blood samples for cystatin C analyses were usually
collected early in the morning and not more than once
a day.
Intensive care unit (ICU)
The study was conducted in a ten-bed general inten-
sive care unit admitting patients from medical and
surgical specialties in a university hospital. Approxi-
mately 1,200–1,500 patients are treated in this unit
each year, with a mean admittance time of 2.5 days.
The unit has an ABL 725 (Radiometer, Copenhagen,
Denmark) blood gas instrument for point of care
testing in the ward.
Sample collection
The samples for creatinine and cystatin C analyses
were collected in gel tubes with lithium-heparin (LH
PST  II, BD Vacutainer Systems, Plymouth, UK).
Table I. GFR markers, drug levels in plasma among the most
frequently ordered tests during the study period 2004–2006 (mean
number of tests per year).
Test n
1. Blood gases (ABL 725) 50725
2. Creatinine 3089
3. Blood cell counts 3070
4. C-reactive protein 3063
5. Activated partial thromboplastin time 2883
6. Prothrombin complex 2797
7. Bilirubin, direct method 1972
8. Alanine aminotransferase (ALT) 1972
17. Pt-GFR (CystC-calculated) 875
25. Vancomycin 182
28. Tobramycin 120
31. Digoxin 84
36. Gentamycin 56
Pt-GFR, Patient-Glomerular ﬁltration rate.
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(eGFR)
Plasma cystatin C measurements were performed by
latex-enhanced reagent (N Latex cystatin C, Dade
Behring, Deerﬁeld, IL, USA) using a Behring BN
ProSpec analyzer(Dade Behring). The total analytical
imprecision of the method was 4.8% at 0.56 mg/L and
3.7% at 2.85 mg/L. The cystatin C results are
reported as a cystatin C-estimated GFR (eGFR) in
mL/min/1.73 m
2 (17). GFR in mL/min/1.73 m
2 was
calculated from cystatin C results in mg/mL by the
equation y = 77.24  (Cystatin C result)
-1.2623 (17).
The reference value for cystatin C-estimated GFR
(eGFR) was ‡ 80 mL/min/1.73 m
2.
Plasma creatinine and Modiﬁcation of Diet in Renal
Disease (MDRD) formula-estimated GFR (eGFR)
Plasma creatinine was analyzed with a modiﬁed kinetic
Jaffé reaction on an Architect Ci8200
  analyzer
(Abbott, Abbott Park, IL, USA) and reported as SI
units (mmol/L). The method is isotope dilution mass
spectrometry (IDMS)-calibrated in collaboration with
the Swedish external quality assurance organization
(Equalis, Uppsala, Sweden). The total analytical
imprecision of the creatinine method was 4.8% at
both 94 and 337 mmol/L. The reference interval for
creatinine concentration in adult males was 60–
100 mmol/L. The reference interval for creatinine con-
centration in adult females was 50–90 mmol/L.
eGFRMDRD was calculated from creatinine using the
MDRD formula: eGFR = 175  (creatinine (mmol/L)/
88.4)
1.154  age (years)
0.203  0.742 (if female)
(18). The factor for African Americans was not used.
Statistical calculations
All calculations were performed with the statistical
software package Statistica 7.0 (StatSoft, Tulsa, OK,
USA). Associations between continuous variables
were tested with Spearman’s rank correlation analysis
(R). P values < 0.05 were regarded as statistically
signiﬁcant throughout the study.
Results
Most frequently ordered tests
The most frequently ordered test was arterial blood
gas analysis. Creatinine was the second most fre-
quently ordered test on the list (Table I). Aminogly-
cosides, vancomycin, and digoxin were the most
frequently ordered drug tests.
Cystatin C and creatinine plasma levels
Duringthestudiedtimeperiodtherewere1,838cysta-
tin C test results. Of these requests 1,151 (63%) were
for male patients and 687 (37%) were for female
patients. The mean age of the patients was 62 years
(62 for both males and females).
Median cystatin C concentration in the cohort was
1.96 mg/L (interquartile range 1.38–2.81 mg/L), and
mean value was 2.23 mg/L. For males the median
cystatin C concentration was 1.99 mg/L (interquartile
range 1.39–2.81 mg/L), and for females the median
cystatin C concentration was 1.90 mg/L (interquartile
range 1.36–2.83 mg/L).
During the time period there were 7,566 requests
for creatinine. Of these requests 4,573 (60%) were for
male patients, and 2,993 (40%) were for female
patients.
Median creatinine concentration in the cohort was
91 mmol/L (interquartile range 67–153 mmol/L),
and mean value was 131 mmol/L. For males the
median creatinine concentration was 99 mmol/L
(interquartile range 73–166 mmol/L), and for females
the median creatinine concentration was 80 mmol/L
(interquartile range 60–132 mmol/L). A total of
2,247 out of 4,573 test results for males were above
the reference interval (49%); 1,234 out of 2,993 test
results for females were above the reference
interval (41%).
In 88% of the patients, plasma cystatin C values
indicated reduced kidney function, whereas only 46%
of the patients had reduced kidney function as eval-
uated by their plasma creatinine levels.
eGFR calculated from cystatin C values
Median eGFRcystatinC in the study group was
30.3 mL/min/1.73 m
2 (interquartile range 17.9–
50.1 mL/min/1.73 m
2), and mean value was
37.6 mL/min/1.73 m
2. For males the median eGFR
was 29.7 mL/min/1.73 m
2 (interquartile range 18.1–
49.7 mL/min/1.73 m
2), and for females the median
eGFRcystatinC was 31.7 mL/min/1.73 m
2 (interquartile
range 17.9–51.4 mL/min/1.73 m
2).
Out of the 1,838 eGFRcystatinC results, only
146 results (7.9%) were within the reference range,
while 92.1% of the results were below the reference
interval. Out of the 1,838 eGFR results, 454 results
(25%) were higher than 50 mL/min/1.73 m
2, and
1,279 (70%) were higher than 20 mL/min/1.73 m
2.
There was a strong negative correlation between
age and eGFR (R = 0.316, P < 0.0001).
Both males (R = 0.302; P < 0.0001) and females
(R = 0.344; P < 0.0001) showed similar negative
correlations (Figures 1 and 2).
GFR in intensive care patients 41Paired plasma cystatin C and creatinine analyses
There were 1,777 test requests that contained both
cystatin C and creatinine results performed on the
same test tube. Of these requests 1,110 were for
males and 667 for females. These samples were
from 734 different patients (median 2.42 samples
per patient).
Median creatinine concentration in this subgroup
was 127 mmol/L (interquartile range 87–207 mmol/L),
and mean value was 167 mmol/L.
For males the median creatinine concentration was
134 mmol/L (interquartile range 95–212 mmol/L), and
for females the median creatinine concentration was
111 mmol/L (interquartile range 76–199 mmol/L).
A total of 789 out of 1,110 test results for males
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Figure 1. A: Age versus cystatin C-estimated glomerular ﬁltration rate (eGFR) for all patients (n = 1,838). B: Age versus cystatin
C-estimated glomerular ﬁltration rate (eGFR) for males (n = 1,151). C: Age versus cystatin C-estimated glomerular ﬁltration rate
(eGFR) for females (n = 687).
42 M. Lipcsey et al.were in the reference interval (71%); 418 out of
667 test results for females were in the reference
interval (63%). In total 1,207 out of 1,777 plasma
creatinine results were pathological (68%).
Out of the MDRD-estimated GFR results 47%
were £80 mL/min/1.73 m
2, 30% were £ 50 mL/min/
1.73 m
2, and 7% £20 mL/min/1.73 m
2. Median
MDRD eGFR was 48 mL/min/1.73 m
2 (Table II).
Out of the 1,777 cystatin C-estimated GFR results
93% were £ 80 mL/min/1.73 m
2,7 4 %w e r e£50 mL/
min/1.73 m
2,a n d2 3 %w e r e£20 mL/min/1.73 m
2.
Median MDRD eGFR was 39 mL/min/1.73 m
2.T h e
Spearman rank correlation between the two methods
was R = 0.753 (Figure 3). MDRD-estimated GFR
yielded higher values than cystatin C-estimated GFR
(Figure 4). The mean difference between eGFRMDRD
and eGFRcystatinC was 39 mL mL/min/1.73 m
2 for
eGFRcystatinC values £ 60 mL/min/1.73 m
2.
Discussion
Plasma creatinine’s role as GFR marker assumes a
steady state condition of creatinine distribution. How-
ever creatinine levels in plasma and urine are subject
to variations during critical illness for several reasons.
Critically ill patients often have increased body water
volume and decreased muscle mass and may have
impaired liver function. Other factors that may inﬂu-
ence creatinine production are trauma, fever, and
immobilization. There is also the problem of tubular
secretion of creatinine to some extent while low urine
production may cause tubular reabsorption. Thus,
creatinine is not an optimal marker for detection of
acute renal failure in intensive care patients; there is
on-going search for better GFR markers, and cystatin
C and proANP (Atrial natriuretic peptide) have been
suggested as alternatives (19). One study that com-
pared cystatin C and creatinine reported that cystatin
C and creatinine performed equally well in intensive
care patients (20). Two other studies showed cystatin
C to be superior to creatinine. One of the studies
reported that serum cystatin C detected acute renal
failure 1 to 2 days earlier than creatinine (21). The
other study compared cystatin C and creatinine with
24-h urine collection and creatinine clearance. Cysta-
tin C was signiﬁcantly better than creatinine to detect
reduced GFR (22). Neither of these studies compared
GFR estimated from cystatin C and creatinine with
GFR measurement using an exogenous marker such
as iohexol, iothalamate, or chromium-51-EDTA.
In this study we show that, apart from arterial blood
gas analysis, GFR markers are the most frequently
requested tests in the ICU. Furthermore we show that
there are considerable differences between the studied
markers creatinine, eGFRMDRD, and eGFRcystatinC
for estimating GFR in ICU patients. Reduced GFR
is very common in this ICU population, especially
when using cystatin C for estimating GFR. There
was a strong negative correlation between age and
eGFRcystatinC, while the correlation between age and
creatinine was less pronounced. This could be
expected as both GFR and muscle mass decrease
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Figure 2. Age versus plasma creatinine for all patients (n = 7,566).
Table II. Percentage of patients with GFR below 20, 50, and
80 mL/min/1.73 m
2, respectively, based on eGFRMDRD and
eGFRcystatinC calculations.
£ 20 mL/
min/1.73m
2
£ 50 mL/
min/1.73 m
2
£ 80 mL/
min/1.73 m
2
eGFRcystatinC 30% 75% 92%
eGFRMDRD 7% 30% 47%
GFR in intensive care patients 43with age. An increased plasma creatinine due to
reduced GFR is thus partly disguised by the reduced
muscle mass. Cystatin C detected twice as high a
frequency of reduced GFR in spite of a high degree of
correlation between these two methods.
Plasma creatinine, eGFRMDRD, and cystatin C
assays can all provide rapid test results. Creatinine
often over-estimates GFR in patients with slight
reductions of GFR (11). It is also difﬁcult to evaluate
creatinine in elderly patients with low muscle mass.
These patients may have creatinine values in the
normal range due to the combination of low muscle
mass and reduced GFR. This is in agreement with the
present results with 92% of the cystatin C values
indicating reduced kidney function, while only 46%
of the creatinine test results indicated a reduced
kidney function. A considerable gap between the
results, 93% versus 47% for eGFR with cystatin C
and eGFR with MDRD, respectively, persisted even
when the two methods were performed on the same
plasma sample. In this study we used the reference
value ‡80 mL/min/1.73 m
2 regardless of patient age as
a decreased eGFR in the range of 50–80 mL/min/
1.73 m
2 was associated with increased mortality in
elderly individuals (23–26).
We included plasma creatinine in this comparison
as many GFR evaluations in Sweden are based on the
creatinine concentration. The GFR estimations from
plasma creatinine values are performed in the wards
either by a rough estimate based on the creatinine
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Figure 4. Bland–Altman bias plot for eGFRcystatinC and eGFRMDRD. The results are presented as the mean of the two methods (x-axis) plotted
against the difference between the two methods (y-axis) (n = 1,777).
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Figure 3. Correlation between cystatin C and creatinine in individual patients (n = 1,668).
44 M. Lipcsey et al.value or by using nomogram for the Cockcroft-
Gault equation (8). The equations are very rarely
performed utilizing computers.
The problems associated with calculating GFR in
the wards have led to the development of formulas to
automatically convert cystatin C in mg/L to a calcu-
lated GFR in mL/min/1.73 m
2 (17,27). This is in
agreement with guidelines that laboratories should
calculate and report an estimated glomerular ﬁltration
rate (eGFR) using the MDRD formula with every
request for plasma creatinine concentration (28). In
the ICU, MDRD and plasma creatinine concentra-
tion detected similar numbers of patients with
reduced GFR, and both methods detected a lower
number of patients with reduced GFR in comparison
with cystatin C-estimated GFR.
Cystatin C has also been suggested to be superior to
creatinine measurements for intensive care use
although this has also been questioned (16,29).
In this study we compared cystatin C as
GFR marker with creatinine concentration and
eGFRMDRD. The study shows that a higher propor-
tion of the intensive care patients had impaired kidney
function when using eGFRcystatinC. Several of the
drugs used in the intensive care unit are eliminated
by the kidneys, and their turn-over is thus inﬂuenced
by the GFR. Determination of plasma concentrations
of digoxin, gentamycin, tobramycin, and vancomycin
are all among the top 40 test requests in the intensive
care unit, and they are all inﬂuenced by the GFR.
Even though concentration of these drugs can be
measured, initial therapy is started based on GFR
estimates. Furthermore, levels of several widely used
pharmaceuticals with renal elimination are not rou-
tinely assessed. Examples of such drugs used in crit-
ical care are H2-antagonists, beta-blockers, and
antibiotics such as penicillins and cephalosporins.
Inadequate dosage of these pharmaceuticals may
lead to insufﬁcient therapy or adverse effects, which
highlight the need for optimal GFR markers or
the advantage of pharmaceuticals without renal
elimination.
Conclusions
The present study shows that GFR is frequently
assessed in the ICU, and many intensive care patients
have reduced GFR, and the study emphasizes the
need to monitor GFR in this patient group. The
use of cystatin C instead of creatinine will increase
the number of patients identiﬁed with decreased
GFR. Since most ICUs use plasma or serum creat-
inine for GFR monitoring, they may miss several
patients with reduced eGFRcystatinC. The discrepancy
between the two methods may inﬂuence the pharma-
ceutical treatment of the patients and shows that there
is a need to improve GFR measurements in intensive
care. Without an optimal GFR marker, using drugs
that are less GFR-dependent should be considered.
With the existing methodological differences in mind,
there is a need for further studies that compare GFR
estimated from cystatin C and creatinine with GFR
measurement with an exogenous marker such as
iohexol, iothalamate, or chromium-51-EDTA in
intensive care patients.
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